EP1901730A1 - Utilisation d'activateurs de la guanylate-cyklase soluble pour le traitement des dommages de la reperfusion - Google Patents

Utilisation d'activateurs de la guanylate-cyklase soluble pour le traitement des dommages de la reperfusion

Info

Publication number
EP1901730A1
EP1901730A1 EP06818217A EP06818217A EP1901730A1 EP 1901730 A1 EP1901730 A1 EP 1901730A1 EP 06818217 A EP06818217 A EP 06818217A EP 06818217 A EP06818217 A EP 06818217A EP 1901730 A1 EP1901730 A1 EP 1901730A1
Authority
EP
European Patent Office
Prior art keywords
medicament
treatment
reperfusion damage
guanylate cyclase
soluble guanylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP06818217A
Other languages
German (de)
English (en)
Inventor
Thomas Krahn
Johannes-Peter Stasch
Gerrit Weimann
Wolfgang Thielemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1901730A1 publication Critical patent/EP1901730A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to the use of compounds for the manufacture of a pharmaceutical product / medicament for the prophylaxis and / or treatment of reperfusion injury.
  • Reperfusion damage generally occurs after the cessation of a prolonged ischemic period, e.g. as a result of invading accumulating toxic metabolites after restoration of blood flow and / or massive release of calcium ions in excitable cells. These damages often occur after vascular occlusions, especially after acute arterial occlusions, when a compensating collateral circulation is absent (so-called infarcts).
  • the best known forms are the heart attack and the cerebral infarction (stroke). While early restoration of blood flow by thrombolysis following transient ischemia may prevent or reduce the extent of cell damage (infarct size), reperfusion may still be to some extent dysfunctional, e.g. of the heart or cause cell death. Therefore, it is of great clinical value to find medicines which inhibit normal function, e.g. of the heart during reperfusion and at various forms of cardiac surgery.
  • ischemic reperfusion injury and associated cellular damage e.g. occur in: Myocardial infarction, replacement of arterial coronary vessels, in particular cardiac surgery on the open chest, angina, peripheral vascular occlusive diseases, stroke, tissue and organ transplants (eg, heart, liver, kidney, lung), general surgery, - acute renal failure and reduced perfusion of Organs (eg lung, heart, liver, intestine, pancreas, kidney, extremities or brain).
  • Elevated cGMP levels may protect cells, tissues, and organs from reperfusion damage.
  • the activation (agonists) of soluble guanylate cyclase leads to an increase of the intracellular messenger cGMP.
  • the compounds of the invention activators of soluble guanylate cyclase are particularly suitable for the preparation of pharmaceutical substances / medicaments for the prophylaxis and / or treatment and the limitation of reperfusion injury in mammals, especially humans.
  • Connection (FVa) corresponds to the following formula: - A -
  • An additional embodiment of the present invention comprises the procedure for the prophylaxis and / or treatment of reperfusion injury using at least one of the compounds of formulas (I-VI).
  • Another object of the present invention are pharmaceutical compositions containing at least one compound of the invention and at least one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
  • the compounds according to the invention can act systemically and / or locally.
  • they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctivae otic or as an implant or stent.
  • the compounds according to the invention can be administered in suitable administration forms.
  • Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
  • a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
  • absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally.
  • parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • inhalant medicines including powder inhalers, nebulizers
  • nasal drops solutions, sprays
  • lingual sublingual or buccal.
  • the compounds according to the invention can be converted into the stated administration forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
  • These adjuvants include, among others. Carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (eg liquid polyethylene glycols), emulsifiers and dispersing or wetting agents (for example sodium dodecyl sulfate, polyoxysorbitanoleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (for example Antioxi - Dantien such as ascorbic acid), dyes (eg, inorganic pigments such as iron oxides) and flavor and / or odoriferous.
  • Carriers for example microcrystalline cellulose, lactose, mannitol
  • solvents eg liquid polyethylene glycols
  • emulsifiers and dispersing or wetting agents for example sodium
  • compositions containing at least one compound of the invention usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
  • the formulations may contain from 0.1 to 99% active ingredient according to the procedure, suitably 25-95% for tablets and capsules and 1-50% for liquid formulations, ie the active ingredient should be present in sufficient amounts reach specified dosage latitude. - 1 -
  • An additional exemplary embodiment of the present invention is the use of a combination of one or more of the compounds according to the invention with one or more other substances.
  • Suitable combinations of substances are, for example, substances which are used for the prophylaxis and / or treatment of infarcts and reperfusion damage.
  • exemplary and preferred in this context are cGMP-increasing substances such as NO-releasing substances, inhibitors of phosphodiesterases, thrombolytics and adenosine agonists.
  • Infarct size was determined at the end of the experiment by quickly removing the isolated heart from the Langendorff setup. After a wash in physiological saline, the coronary artery was resealed and fluorescent microspheres infused into the heart to represent the risk zone or ischemic area as non-fluorescent tissue. After the heart was weighed and deep frozen, it could be sliced into 2mm thick slices. These disks were incubated in 1% triphenyltetrazolium chloride (TTC) in sodium phosphate buffer at 37 ° C for 20 minutes. The viable tissue is dyed dark red whereas the necrotic tissue does not stain and appear brownish.
  • TTC triphenyltetrazolium chloride
  • soluble guanylate cyclase activators are useful in reducing infarct size and reducing reperfusion injury.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de la production d'un produit pharmaceutique/médicament pour la prévention et/ou le traitement des dommages de reperfusion.
EP06818217A 2005-07-06 2006-07-06 Utilisation d'activateurs de la guanylate-cyklase soluble pour le traitement des dommages de la reperfusion Ceased EP1901730A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005031576A DE102005031576A1 (de) 2005-07-06 2005-07-06 Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Reperfusionsschäden
PCT/EP2006/006600 WO2007025595A1 (fr) 2005-07-06 2006-07-06 Utilisation d'activateurs de la guanylate-cyklase soluble pour le traitement des dommages de la reperfusion

Publications (1)

Publication Number Publication Date
EP1901730A1 true EP1901730A1 (fr) 2008-03-26

Family

ID=37433912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06818217A Ceased EP1901730A1 (fr) 2005-07-06 2006-07-06 Utilisation d'activateurs de la guanylate-cyklase soluble pour le traitement des dommages de la reperfusion

Country Status (14)

Country Link
US (1) US20090298822A1 (fr)
EP (1) EP1901730A1 (fr)
JP (1) JP2009500365A (fr)
KR (1) KR20080033238A (fr)
CN (1) CN101257901A (fr)
AU (1) AU2006286896A1 (fr)
BR (1) BRPI0612685A2 (fr)
CA (1) CA2614088A1 (fr)
DE (1) DE102005031576A1 (fr)
IL (1) IL188584A0 (fr)
MX (1) MX2008000276A (fr)
RU (1) RU2432948C2 (fr)
WO (1) WO2007025595A1 (fr)
ZA (1) ZA200800025B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026392A1 (de) * 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
ES2572638T3 (es) * 2010-07-09 2016-06-01 Bayer Intellectual Property Gmbh 4-Aminopirimidinas condensadas y su uso como estimuladores de la guanilatociclasa soluble
BR112014000268A2 (pt) * 2011-07-06 2017-04-25 Bayer Ip Gmbh pirazolopiridinas com substituinte heteroarilo e utilização destas
WO2013082458A1 (fr) 2011-12-02 2013-06-06 The Regents Of The University Of California Solution de protection de reperfusion et ses utilisations
ES2616042T3 (es) * 2013-03-01 2017-06-09 Bayer Pharma Aktiengesellschaft Pirazolopiridinas sustituidas con bencilo y su uso

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040332A2 (fr) * 2001-11-06 2003-05-15 Buck Institute L'elevation de la production de neuroglobine lors d'agressions hypoxiques-ischemiques protege les neurones contre ces memes agressions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US173514A (en) * 1876-02-15 Improvement in call-bells
DE69928260T2 (de) * 1998-07-08 2006-07-20 Sanofi-Aventis Deutschland Gmbh Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
US20050255178A1 (en) * 2004-02-04 2005-11-17 Bloch Kenneth D Enhancing the effectiveness of an inhaled therapeutic gas
CA2583073A1 (fr) * 2004-10-05 2006-04-13 Bayer Healthcare Ag Stimulateur de guanylate cyclase et oxyde nitrique utiles dans le traitement de la bronchoconstriction et de la vasoconstriction pulmonaire

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040332A2 (fr) * 2001-11-06 2003-05-15 Buck Institute L'elevation de la production de neuroglobine lors d'agressions hypoxiques-ischemiques protege les neurones contre ces memes agressions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2007025595A1 *
YANG XI-MING ET AL: "Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation.", BASIC RESEARCH IN CARDIOLOGY JAN 2005 LNKD- PUBMED:15614590, vol. 100, no. 1, January 2005 (2005-01-01), pages 57 - 63, ISSN: 0300-8428 *

Also Published As

Publication number Publication date
CN101257901A (zh) 2008-09-03
JP2009500365A (ja) 2009-01-08
AU2006286896A1 (en) 2007-03-08
IL188584A0 (en) 2008-06-05
DE102005031576A1 (de) 2007-01-25
RU2432948C2 (ru) 2011-11-10
KR20080033238A (ko) 2008-04-16
RU2008103549A (ru) 2009-08-20
CA2614088A1 (fr) 2007-03-08
WO2007025595A1 (fr) 2007-03-08
BRPI0612685A2 (pt) 2010-11-30
MX2008000276A (es) 2008-03-19
US20090298822A1 (en) 2009-12-03
ZA200800025B (en) 2009-09-30

Similar Documents

Publication Publication Date Title
EP0639074B1 (fr) Medicament contre l'ischemie
DE10019062A1 (de) 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
WO2007025595A1 (fr) Utilisation d'activateurs de la guanylate-cyklase soluble pour le traitement des dommages de la reperfusion
WO2001072742A1 (fr) Composes bisamidino utilises comme inhibiteurs de nhe-3
JP2574585B2 (ja) 再潅流損傷の防止又は制限のための薬剤
DE60225434T2 (de) Cumarin derivate und ihre verwendung als antikoagulantien
EP1901732A2 (fr) Utilisation d'activateurs de la guanylate cyclase soluble pour favoriser la guerison de blessures
EP1945218A2 (fr) Utilisation d'activateurs de la cyclase de guanylate destinee a traiter des maladies pulmonaires aigues et chroniques
DE10043667A1 (de) 2-Guanidino-4-aryl-chinazoline
DE69917074T2 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
DE102005047945A1 (de) Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen
DE10223013A1 (de) Verwendung von Meloxicam für die Linderung von Organverletzungen während Organoperation oder -transplantation
DE69933347T2 (de) Vorbeugung und Behandlung von Krankheiten in Zusammenhang zu vaskularen funktionellen Störungen in Verbindung mit Insulinresistenz
DE60313886T2 (de) Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Behandlung von Obesitas
WO2000059890A1 (fr) Derives de tetrahydropyridazine
DE69828390T2 (de) Antikrebs-zusammensetzung
EP1362030B1 (fr) Sel de benzoylguanidine
DE3344755A1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten
JP2710633B2 (ja) 心臓疾患治療剤
RU2333202C2 (ru) 2-(бутил-1-сульфониламино)-n-[1(r)-(6-метоксипиридин-3-ил)-пропил]бензамид, его применение в качестве лекарственного средства, а также содержащие его фармацевтические композиции
WO2001000188A2 (fr) Derives de tetrahydrochinolinyl-6-methyldihydrothiadiazinone et leur utilisation
SK5512002A3 (en) Use of 2-imidazolyl substituted carbinols for production of a medicament for treatment or prophylaxis of disease states as a result of ischaemic conditions
DD284601A5 (de) Verfahren zur herstellung eines arzneimittels
WO2018153897A1 (fr) Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs des canaux hcn
SA98190540B1 (ar) جرعة مشتركة ثابتة تحتوي على مثبط لأنزيم تحويل الأنجيوتنسين وعلى عامل مضاد لقناة الكالسيوم لعلاج الأمراض القلبية الوعائية

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090316

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130225